JP2003502388A - モノホスホリルリピドａの水性免疫学的アジュバント組成物 - Google Patents
モノホスホリルリピドａの水性免疫学的アジュバント組成物Info
- Publication number
- JP2003502388A JP2003502388A JP2001504415A JP2001504415A JP2003502388A JP 2003502388 A JP2003502388 A JP 2003502388A JP 2001504415 A JP2001504415 A JP 2001504415A JP 2001504415 A JP2001504415 A JP 2001504415A JP 2003502388 A JP2003502388 A JP 2003502388A
- Authority
- JP
- Japan
- Prior art keywords
- lipid
- derivative
- immunostimulatory
- aqueous
- adjuvant composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 94
- 229940035032 monophosphoryl lipid a Drugs 0.000 title claims abstract description 64
- 239000000568 immunological adjuvant Substances 0.000 title description 2
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical class O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 claims abstract description 46
- 102000036639 antigens Human genes 0.000 claims abstract description 41
- 108091007433 antigens Proteins 0.000 claims abstract description 41
- 239000004094 surface-active agent Substances 0.000 claims abstract description 39
- 239000000427 antigen Substances 0.000 claims abstract description 35
- 230000003308 immunostimulating effect Effects 0.000 claims abstract description 35
- 230000002238 attenuated effect Effects 0.000 claims abstract description 32
- 239000002671 adjuvant Substances 0.000 claims abstract description 28
- 241001465754 Metazoa Species 0.000 claims abstract description 17
- 239000002904 solvent Substances 0.000 claims abstract description 15
- 210000002966 serum Anatomy 0.000 claims abstract description 12
- 238000004519 manufacturing process Methods 0.000 claims abstract description 8
- 230000028993 immune response Effects 0.000 claims abstract description 7
- 230000004044 response Effects 0.000 claims abstract description 7
- 230000003248 secreting effect Effects 0.000 claims abstract description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 39
- 238000000034 method Methods 0.000 claims description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
- 239000000725 suspension Substances 0.000 claims description 16
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 13
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 10
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 8
- 238000000527 sonication Methods 0.000 claims description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 claims description 3
- NEZDNQCXEZDCBI-WJOKGBTCSA-N (2-aminoethoxy)[(2r)-2,3-bis(tetradecanoyloxy)propoxy]phosphinic acid Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CCCCCCCCCCCCC NEZDNQCXEZDCBI-WJOKGBTCSA-N 0.000 claims description 3
- 108010035713 Glycodeoxycholic Acid Proteins 0.000 claims description 3
- 229940009976 deoxycholate Drugs 0.000 claims description 3
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 claims description 3
- WVULKSPCQVQLCU-BUXLTGKBSA-N glycodeoxycholic acid Chemical group C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 WVULKSPCQVQLCU-BUXLTGKBSA-N 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 3
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 claims description 3
- 230000002708 enhancing effect Effects 0.000 claims description 2
- 238000001704 evaporation Methods 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 230000004936 stimulating effect Effects 0.000 claims description 2
- SUHOQUVVVLNYQR-MRVPVSSYSA-O glycerylphosphorylcholine Chemical compound C[N+](C)(C)CCO[P@](O)(=O)OC[C@H](O)CO SUHOQUVVVLNYQR-MRVPVSSYSA-O 0.000 claims 3
- 230000001939 inductive effect Effects 0.000 claims 2
- 238000005352 clarification Methods 0.000 claims 1
- 238000009472 formulation Methods 0.000 abstract description 11
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 abstract description 10
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 abstract description 8
- 230000005875 antibody response Effects 0.000 abstract description 4
- 210000004698 lymphocyte Anatomy 0.000 abstract description 2
- 230000035755 proliferation Effects 0.000 abstract 1
- 229960000814 tetanus toxoid Drugs 0.000 description 26
- 241000699670 Mus sp. Species 0.000 description 25
- 210000004027 cell Anatomy 0.000 description 18
- 230000003053 immunization Effects 0.000 description 16
- 238000002649 immunization Methods 0.000 description 16
- 239000013011 aqueous formulation Substances 0.000 description 15
- 239000002158 endotoxin Substances 0.000 description 11
- 229960005486 vaccine Drugs 0.000 description 11
- 239000002609 medium Substances 0.000 description 9
- 238000006460 hydrolysis reaction Methods 0.000 description 8
- 229920006008 lipopolysaccharide Polymers 0.000 description 8
- 239000002245 particle Substances 0.000 description 8
- 230000007062 hydrolysis Effects 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 108010058846 Ovalbumin Proteins 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 150000004665 fatty acids Chemical group 0.000 description 6
- 238000004108 freeze drying Methods 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 230000028996 humoral immune response Effects 0.000 description 5
- 229940092253 ovalbumin Drugs 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 210000004988 splenocyte Anatomy 0.000 description 5
- 239000008215 water for injection Substances 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 4
- 230000024932 T cell mediated immunity Effects 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 230000003389 potentiating effect Effects 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000002784 cytotoxicity assay Methods 0.000 description 3
- 231100000263 cytotoxicity test Toxicity 0.000 description 3
- 238000005947 deacylation reaction Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229960002442 glucosamine Drugs 0.000 description 3
- 208000002672 hepatitis B Diseases 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000009696 proliferative response Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 210000002925 A-like Anatomy 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 101710154606 Hemagglutinin Proteins 0.000 description 2
- 231100000111 LD50 Toxicity 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 2
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 2
- 101710176177 Protein A56 Proteins 0.000 description 2
- 241001222774 Salmonella enterica subsp. enterica serovar Minnesota Species 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000002096 anti-tetanic effect Effects 0.000 description 2
- 239000012062 aqueous buffer Substances 0.000 description 2
- 239000003833 bile salt Substances 0.000 description 2
- 229940093761 bile salts Drugs 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000006184 cosolvent Substances 0.000 description 2
- 230000020176 deacylation Effects 0.000 description 2
- 239000010432 diamond Substances 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 230000002550 fecal effect Effects 0.000 description 2
- 239000000185 hemagglutinin Substances 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 229960003971 influenza vaccine Drugs 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 150000004668 long chain fatty acids Chemical class 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 102220240796 rs553605556 Human genes 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 150000003408 sphingolipids Chemical class 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- ATRNZOYKSNPPBF-CYBMUJFWSA-N (R)-3-hydroxytetradecanoic acid Chemical compound CCCCCCCCCCC[C@@H](O)CC(O)=O ATRNZOYKSNPPBF-CYBMUJFWSA-N 0.000 description 1
- IQFYYKKMVGJFEH-OFKYTIFKSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(tritiooxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO[3H])O[C@H]1N1C(=O)NC(=O)C(C)=C1 IQFYYKKMVGJFEH-OFKYTIFKSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- ATRNZOYKSNPPBF-UHFFFAOYSA-N D-beta-hydroxymyristic acid Natural products CCCCCCCCCCCC(O)CC(O)=O ATRNZOYKSNPPBF-UHFFFAOYSA-N 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- 101000879758 Homo sapiens Sjoegren syndrome nuclear autoantigen 1 Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 102100037330 Sjoegren syndrome nuclear autoantigen 1 Human genes 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000007893 endotoxin activity Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 210000004013 groin Anatomy 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000037797 influenza A Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000016379 mucosal immune response Effects 0.000 description 1
- 229940042880 natural phospholipid Drugs 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- VOXDTCSXQHOYKC-XGEOUJBZSA-N palmitoyllipid A Chemical compound O[C@H]1[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)[C@@H](OP(O)(O)=O)O[C@@H]1CO[C@H]1[C@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@H](OP(O)(O)=O)[C@@H](CO)O1 VOXDTCSXQHOYKC-XGEOUJBZSA-N 0.000 description 1
- 239000003444 phase transfer catalyst Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- YHHSONZFOIEMCP-UHFFFAOYSA-O phosphocholine Chemical compound C[N+](C)(C)CCOP(O)(O)=O YHHSONZFOIEMCP-UHFFFAOYSA-O 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 230000027317 positive regulation of immune response Effects 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 235000011118 potassium hydroxide Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229940021993 prophylactic vaccine Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 230000001698 pyrogenic effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- PXLIDIMHPNPGMH-UHFFFAOYSA-N sodium chromate Chemical compound [Na+].[Na+].[O-][Cr]([O-])(=O)=O PXLIDIMHPNPGMH-UHFFFAOYSA-N 0.000 description 1
- 235000011121 sodium hydroxide Nutrition 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 229960001005 tuberculin Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
- C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
- C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
- C07H13/06—Fatty acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Otolaryngology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/338,182 US6491919B2 (en) | 1997-04-01 | 1999-06-22 | Aqueous immunologic adjuvant compostions of monophosphoryl lipid A |
| US09/338,182 | 1999-06-22 | ||
| PCT/US2000/016384 WO2000078353A2 (en) | 1999-06-22 | 2000-06-14 | Aqueous immunologic adjuvant compositions of monophosphoryl lipid a |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003502388A true JP2003502388A (ja) | 2003-01-21 |
| JP2003502388A5 JP2003502388A5 (https=) | 2007-08-02 |
Family
ID=23323749
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001504415A Pending JP2003502388A (ja) | 1999-06-22 | 2000-06-14 | モノホスホリルリピドａの水性免疫学的アジュバント組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US6491919B2 (https=) |
| EP (1) | EP1194166B1 (https=) |
| JP (1) | JP2003502388A (https=) |
| AT (1) | ATE381344T1 (https=) |
| AU (1) | AU775942B2 (https=) |
| CA (1) | CA2376829A1 (https=) |
| DE (1) | DE60037514T2 (https=) |
| ES (1) | ES2296629T3 (https=) |
| WO (1) | WO2000078353A2 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025058011A1 (ja) * | 2023-09-13 | 2025-03-20 | 国立大学法人大阪大学 | 経鼻投与用組成物 |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9706957D0 (en) | 1997-04-05 | 1997-05-21 | Smithkline Beecham Plc | Formulation |
| GB9820525D0 (en) | 1998-09-21 | 1998-11-11 | Allergy Therapeutics Ltd | Formulation |
| GB0000891D0 (en) * | 2000-01-14 | 2000-03-08 | Allergy Therapeutics Ltd | Formulation |
| US20030139356A1 (en) * | 2001-05-18 | 2003-07-24 | Persing David H. | Prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compounds |
| EP2000144A1 (en) * | 2000-05-19 | 2008-12-10 | Corixa Corporation | Prophylactic and therapeutic treatment of infectious, autoimmune and allergic diseases with mono-and disaccharide-based compounds |
| US20030031684A1 (en) | 2001-03-30 | 2003-02-13 | Corixa Corporation | Methods for the production of 3-O-deactivated-4'-monophosphoryl lipid a (3D-MLA) |
| CA2623197A1 (en) * | 2005-09-22 | 2007-03-29 | Prosci Incorporated | Glycosylated polypeptides produced in yeast mutants and methods of use thereof |
| US7622128B2 (en) * | 2005-12-13 | 2009-11-24 | University Of Washington | Porphyromonas gingivalis 1435/1449 LPS as an immune modulator |
| US7848801B2 (en) | 2005-12-30 | 2010-12-07 | Tti Ellebeau, Inc. | Iontophoretic systems, devices, and methods of delivery of active agents to biological interface |
| US20090181078A1 (en) | 2006-09-26 | 2009-07-16 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
| PT2468300T (pt) | 2006-09-26 | 2018-01-30 | Infectious Disease Res Inst | Composição para vacina contendo adjuvante sintético |
| SG10202012986SA (en) | 2006-09-29 | 2021-01-28 | Ligocyte Pharmaceuticals Inc | Norovirus vaccine formulations |
| US20100266636A1 (en) * | 2007-09-18 | 2010-10-21 | Ligocyte Pharmaceuticals, Inc. | Method of conferring a protective immune response to norovirus |
| JP2010539192A (ja) | 2007-09-18 | 2010-12-16 | リゴサイト ファーマスーティカルズ，インコーポレイテッド | ノロウイルスに対して防御免疫応答を付与する方法 |
| AU2009248810B2 (en) * | 2008-05-23 | 2013-12-05 | The Regents Of The University Of Michigan | Nanoemulsion vaccines |
| AU2009279456B2 (en) | 2008-08-08 | 2015-02-05 | Takeda Vaccines, Inc. | Virus-like particles comprising composite capsid amino acid sequences for enhanced cross reactivity |
| EP2349209A2 (en) | 2008-09-26 | 2011-08-03 | Nanobio Corporation | Nanoemulsion therapeutic compositions and methods of using the same |
| CN102481312B (zh) | 2009-06-05 | 2015-07-15 | 传染性疾病研究院 | 合成的吡喃葡萄糖脂佐剂 |
| BRPI1014031A2 (pt) * | 2009-06-16 | 2018-02-20 | Univ Michigan Regents | vacinas de nanoemulsão |
| WO2012141984A1 (en) | 2011-04-08 | 2012-10-18 | Immune Design Corp. | Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses |
| CA2841356C (en) | 2011-07-11 | 2022-03-01 | Takeda Vaccines, Inc. | Parenteral norovirus vaccine formulations |
| WO2013038185A1 (en) | 2011-09-12 | 2013-03-21 | Jonathan Norden Weber | Methods and compositions for raising an immune response to hiv |
| KR102136433B1 (ko) | 2012-05-16 | 2020-07-22 | 이뮨 디자인 코포레이션 | Hsv-2 백신 |
| EP2986303B1 (en) | 2013-04-18 | 2020-02-26 | Immune Design Corp. | Gla monotherapy for use in cancer treatment |
| US9463198B2 (en) | 2013-06-04 | 2016-10-11 | Infectious Disease Research Institute | Compositions and methods for reducing or preventing metastasis |
| US20150086592A1 (en) | 2013-09-25 | 2015-03-26 | Sequoia Sciences, Inc | Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections |
| WO2015179270A2 (en) | 2014-05-19 | 2015-11-26 | Board Of Regents, The University Of Texas System | Combinatorial platform for the display of surface adjuvants and antigens |
| EP3069729A1 (en) | 2015-03-17 | 2016-09-21 | Sequoia Sciences, Inc. | Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections |
| US20190275134A1 (en) | 2018-03-12 | 2019-09-12 | Janssen Pharmaceuticals, Inc | Vaccines against urinary tract infections |
| CR20210522A (es) | 2019-03-18 | 2021-12-17 | Janssen Pharmaceuticals Inc | Bioconjugados de antígenos–polisacáridos de e. coli, métodos de producción y métodos de utilización de los mismos |
| IL286467B2 (en) | 2019-03-18 | 2026-02-01 | Janssen Pharmaceuticals Inc | Methods for producing bioconjugates of polysaccharides E. coli o-antigen, preparations thereof and methods for using them |
| MX2022004061A (es) | 2019-10-02 | 2022-07-19 | Janssen Vaccines & Prevention Bv | Peptidos de estafilococo y metodos de uso. |
| LT4090363T (lt) | 2020-01-16 | 2024-09-25 | Janssen Pharmaceuticals, Inc. | Fimh mutantas, kompozicijos su juo ir jų panaudojimas |
| IL308201A (en) | 2020-09-17 | 2024-01-01 | Janssen Pharmaceuticals Inc | Multivalent vaccine compositions and uses thereof |
| US11725028B2 (en) | 2021-01-12 | 2023-08-15 | Janssen Pharmaceuticals, Inc. | FimH mutants, compositions therewith and use thereof |
| KR20230164108A (ko) | 2021-04-01 | 2023-12-01 | 얀센 파마슈티칼즈, 인코포레이티드 | E. coli O18 생물접합체의 생산 |
| WO2022251455A1 (en) * | 2021-05-27 | 2022-12-01 | Revelation Biosciences, Inc. | Methods of treating or preventing allergies and chronic nasal congestion |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05508653A (ja) * | 1990-07-18 | 1993-12-02 | バクシン・フランス・エス・アー | 水性溶媒に可溶化し得る疎水性医薬の有効成分をベースとする組成物、その製法、及び特に医薬分野におけるその使用 |
| JPH08508978A (ja) * | 1993-01-22 | 1996-09-24 | スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ | Ｑｓ−２１を伴う、ガングリオシド‐ｋｌｈ複合体 |
| WO1998043670A2 (en) * | 1997-04-01 | 1998-10-08 | Ribi Immunochem Research, Inc. | Aqueous immunologic adjuvant compositions of monophosphoryl lipid a |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4436727A (en) * | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
| US4436728A (en) * | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
| US5554372A (en) * | 1986-09-22 | 1996-09-10 | Emory University | Methods and vaccines comprising surface-active copolymers |
| US4912094B1 (en) * | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| US5068191A (en) * | 1989-08-31 | 1991-11-26 | The Biomembrane Institute | Purified histo-blood group a glycosyltransferase and antibodies thereto |
| US5552141A (en) * | 1991-10-30 | 1996-09-03 | Ribi; Hans O. | Polymeric immunological adjuvants |
| ATE157882T1 (de) | 1993-03-23 | 1997-09-15 | Smithkline Beecham Biolog | 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen |
| US5855913A (en) | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
| US5985309A (en) * | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
| HK1039072A1 (zh) | 1998-05-07 | 2002-04-12 | 科里克萨有限公司 | 佐剂组合物及其使用方法 |
-
1999
- 1999-06-22 US US09/338,182 patent/US6491919B2/en not_active Expired - Lifetime
-
2000
- 2000-06-14 WO PCT/US2000/016384 patent/WO2000078353A2/en not_active Ceased
- 2000-06-14 CA CA002376829A patent/CA2376829A1/en not_active Abandoned
- 2000-06-14 ES ES00944677T patent/ES2296629T3/es not_active Expired - Lifetime
- 2000-06-14 EP EP00944677A patent/EP1194166B1/en not_active Expired - Lifetime
- 2000-06-14 AU AU58738/00A patent/AU775942B2/en not_active Ceased
- 2000-06-14 DE DE60037514T patent/DE60037514T2/de not_active Expired - Fee Related
- 2000-06-14 JP JP2001504415A patent/JP2003502388A/ja active Pending
- 2000-06-14 AT AT00944677T patent/ATE381344T1/de not_active IP Right Cessation
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05508653A (ja) * | 1990-07-18 | 1993-12-02 | バクシン・フランス・エス・アー | 水性溶媒に可溶化し得る疎水性医薬の有効成分をベースとする組成物、その製法、及び特に医薬分野におけるその使用 |
| JPH08508978A (ja) * | 1993-01-22 | 1996-09-24 | スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ | Ｑｓ−２１を伴う、ガングリオシド‐ｋｌｈ複合体 |
| WO1998043670A2 (en) * | 1997-04-01 | 1998-10-08 | Ribi Immunochem Research, Inc. | Aqueous immunologic adjuvant compositions of monophosphoryl lipid a |
Non-Patent Citations (1)
| Title |
|---|
| JPN6010036250, Ｏｚｅｒ，Ｙ． ｅｔ ａｌ．, "Ｉｎｆｌｕｅｎｃｅ ｏｆ ｆｒｅｅｚｉｎｇ ａｎｄ ｆｒｅｅｚｅ−ｄｒｙｉｎｇ ｏｎ ｔｈｅ ｓｔａｂｉｌｉｔｙ ｏｆ ｌｉｐｏｓｏｍｅｓ ｄｉｓｐｅｒｓｅｄ ｉｎ ａｑｕｅｏｕｓ ｍｅｄｉａ", Ａｃｔａ Ｐｈａｒｍ． Ｔｅｃｈｎｏｌ．, 1988, Ｖｏｌ．３４，Ｎｏ．３, Ｐ．１２９−１３９ * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025058011A1 (ja) * | 2023-09-13 | 2025-03-20 | 国立大学法人大阪大学 | 経鼻投与用組成物 |
Also Published As
| Publication number | Publication date |
|---|---|
| AU775942B2 (en) | 2004-08-19 |
| DE60037514D1 (de) | 2008-01-31 |
| CA2376829A1 (en) | 2000-12-28 |
| ATE381344T1 (de) | 2008-01-15 |
| WO2000078353A2 (en) | 2000-12-28 |
| ES2296629T3 (es) | 2008-05-01 |
| US6491919B2 (en) | 2002-12-10 |
| EP1194166B1 (en) | 2007-12-19 |
| AU5873800A (en) | 2001-01-09 |
| DE60037514T2 (de) | 2008-12-24 |
| WO2000078353A3 (en) | 2001-03-15 |
| US20020009456A1 (en) | 2002-01-24 |
| EP1194166A2 (en) | 2002-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003502388A (ja) | モノホスホリルリピドａの水性免疫学的アジュバント組成物 | |
| JP5019494B2 (ja) | モノホスホリルリピドａの水性免疫アジュバント組成物 | |
| JP2003502388A5 (https=) | ||
| AU755445B2 (en) | Adjuvant composition and methods for its use | |
| JP2648305B2 (ja) | 多糖類ワクチン | |
| AU771205B2 (en) | Novel, non-antigenic, mucosal adjuvant formulation which modulates the effects of substances, including vaccine antigens, in contact with mucosal body surfaces | |
| JP2000103745A (ja) | 処方物 | |
| KR101136107B1 (ko) | 알킬포스파티딜콜린과 혼합된 백신 조성물 | |
| EP1395262A2 (en) | Nucleoside vaccine adjuvants | |
| AU2916302A (en) | Aqueous immunologic adjuvant compositions of monophosphoryl lipid | |
| HK1026613B (en) | Aqueous immunologic adjuvant compositions of monophosphoryl lipid a | |
| MXPA99009052A (en) | Aqueous immunologic adjuvant compositions of monophosphoryl lipid a | |
| BRPI0103887B1 (pt) | composições imunogênicas contendo microesferas biodegradáveis encapsulando antígenos, vetores gênicos e adjuvantes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20070604 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20070604 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070604 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20070604 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20070604 |
|
| RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20080327 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20090109 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100629 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20110125 |